Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Daratumumab + FT576 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Daratumumab | Darzalex | JNJ-54767414 | CD38 Antibody 20 | Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov). |
FT576 | FT-576|FT 576 | FT576 are iPSC-derived CAR-NK cells that have been engineered to express a recombinant IL-15/IL-15 receptor signaling complex, a high-affinity, non-cleavable CD16, and a chimeric antigen receptor targeted against BCMA, and to eliminate CD38 expression, which may lead to tumor regression and growth delay (Cancer Res 2021;81(13_Suppl):Abstract nr 1550). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05182073 | Phase I | Cyclophosphamide + Fludarabine FT576 Daratumumab + FT576 | FT576 in Subjects With Multiple Myeloma | Active, not recruiting | USA | 0 |